IGF-1 LR3: What the Evidence Actually Shows
A clear-eyed look at IGF-1 LR3: solid animal pharmacology, no human trials, and a serious cancer signal that self-experimenters should not ignore.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-06-13An engineered IGF-1 analogue that evades IGF-binding proteins to act directly on the IGF-1 receptor. Potent anabolic signalling in animals and cells, but zero human trials — and a serious cancer signal (a mouse study showed accelerated tumour growth, consistent with IGF-1↔cancer epidemiology). No approval; WADA-prohibited (S2.3).
Well-characterised: ~1000× lower IGFBP affinity raises the free fraction acting on IGF1R (PI3K/Akt).
Consistent anabolic/anti-catabolic data in rodents and livestock; potent in cell culture.
No human clinical trials at all; no IND programme.
Animal anabolic effects only; the dominant real-world use is as a bioreactor cell-culture reagent.
No human safety data; a clear animal cancer signal and large human IGF-1↔cancer epidemiology.
Research reagent; no clinical development.
Confident on mechanism and the cancer concern; human efficacy entirely unproven.
Unapproved; WADA-prohibited (S2.3 Growth Factors); grey-market.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
An engineered IGF-1 analogue that acts directly on the IGF-1 receptor. Potent anabolic signalling in animals and cells, but zero human clinical trials; its main legitimate use is as a cell-culture reagent.
Safety snapshot
No human safety data, and a concrete cancer signal — a mouse study showed accelerated tumour growth, consistent with large human epidemiology linking higher IGF-1 to increased cancer risk — plus hypoglycaemia and uncontrolled-overgrowth concerns.
Regulatory & legality
Unapproved; WADA-prohibited (Growth Factors); grey-market.
Where claims can exceed the evidence
Animal anabolic effects do not establish human benefit, and the cancer concern is a serious, evidence-based flag rather than a hypothetical.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
IGF-1 LR3 (Long R3 IGF-1) is one of the most talked-about compounds in physique circles, and one of the most poorly understood. Here is the blunt version up front: the published pharmacology is genuinely solid, but every shred of efficacy data comes from cell cultures, rats, mice and cattle. There are no human clinical trials, no regulatory approval anywhere, and no completed Investigational New Drug programme [14]. Its biggest legitimate real-world job is not building muscle in people at all — it is keeping cells alive in industrial bioreactors [11].
So when you read that LR3 is a "longer-acting, more potent IGF-1", that part is broadly supported by the science. The leap from there to "and therefore it safely builds muscle in humans" is not. This article walks through what is actually known, what is extrapolated, and where the real risks sit.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
CJC-1295 With DAC: The GHRH Analog That Made It to Human Trials
An evidence-first look at CJC-1295 with DAC: real human PK/PD data, how albumin-binding extends its half-life to days, and why development was halted.
CJC-1295 Without DAC (Mod GRF 1-29): What the Evidence Actually Shows
A plain-English, evidence-first look at CJC-1295 without DAC: what it is, why its half-life is short, what the research does and does not show, and the real risks.
GHRP-2 (Pralmorelin): What the Evidence Actually Shows
GHRP-2 reliably triggers a growth hormone pulse and ramps up hunger, but the physique and longevity claims rest on weak, mostly acute data.
GHRP-6: The Original GH-Releasing Peptide That Started It All
GHRP-6 is the first GH-releasing hexapeptide and ghrelin-receptor agonist — strong acute GH evidence, robust hunger effect, but largely superseded by cleaner analogues.